National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 7 of 2001)

Overview

The National Health Act 1953 was enacted by the Parliament of Australia to provide for the administration of national health services and the supply of pharmaceutical benefits, among other things. This legislation established the framework for the Pharmaceutical Benefits Scheme (PBS), which ensures the provision of affordable medications to Australians. The Act was introduced to address the need for a structured system that could make essential medicines accessible and affordable to the population. In this context, the Pharmaceutical Benefits Declaration under subsection 85(2AA) of the Act is a legislative instrument made by a delegate of the Minister for Health and Aged Care, following advice from the Pharmaceutical Benefits Advisory Committee. This specific declaration, made on 1 August 2001, removes certain drugs and medicinal preparations, such as Nadroparin Calcium, from the scope of Part VII of the National Health Act 1953, thereby altering their status under the PBS. The policy objective of such a declaration is to ensure the PBS remains responsive to new medical evidence and changing healthcare needs.

Scope and Application

The Pharmaceutical Benefits Declaration made under subsection 85(2AA) of the National Health Act 1953 applies specifically to the cessation of certain drugs and medicinal preparations from the Pharmaceutical Benefits Scheme (PBS). This Act applies to the entities and individuals involved in the supply, prescription, or provision of these drugs and medicinal preparations, particularly focusing on Nadroparin Calcium as specified in the Schedule to this Declaration. The geographic reach of this Act is nationwide, as the PBS is a Commonwealth-administered scheme impacting all states and territories within Australia. The Act does not explicitly state exclusions or exemptions, but its application is limited to the drugs listed in the Schedule. The scope of the Act can be further extended or modified through subordinate instruments issued under the authority of the Minister for Health and Aged Care, thereby allowing for the dynamic management of the Pharmaceutical Benefits Scheme.

Key Provisions

The National Health Act 1953, through its legislative instrument F2007B01080, includes a declaration under subsection 85(2AA) (section 2). This particular declaration, made by Brett Anthony Lennon, Assistant Secretary of the Pharmaceutical Benefits Branch, and Delegate of the Minister for Health and Aged Care, specifies that certain drugs and medicinal preparations will no longer be subject to Part VII of the National Health Act 1953. The drugs identified in the Schedule of this declaration are those that will cease to be covered, and the declaration commences on 1 August 2001. In accordance with the requirements of the Act, the obligations of the parties involved revolve around the implementation of this declaration. The Assistant Secretary, acting on behalf of the Minister, has obtained the necessary advice from the Pharmaceutical Benefits Advisory Committee as required by subsection 85(2AB). This advice ensures that the decision to remove certain drugs from the coverage of Part VII is informed and based on appropriate considerations. The Minister, through the Assistant Secretary, then makes the declaration as stipulated in the Act, effectively changing the legal status of the specified drugs. Breaches of the provisions in the National Health Act 1953 could result in various consequences, depending on the nature of the non-compliance. While the specific declaration does not outline penalties for non-compliance, general provisions within the Act or other related regulations may impose fines or other sanctions for improper actions. It is important for all parties to adhere to the declared changes to avoid any potential legal ramifications. The specific penalties for breaches would be determined by the relevant provisions of the Act and any related legislation.